<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02915796</url>
  </required_header>
  <id_info>
    <org_study_id>2016-xjs-08</org_study_id>
    <nct_id>NCT02915796</nct_id>
  </id_info>
  <brief_title>Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty</brief_title>
  <official_title>Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty: A Randomized Controlled Clinical Trial in Diabetic Patients With Below the Knee Critical Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 10th People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of the present study was to evaluate the therapeutic potential and safety of
      transarterial infusion of granulocyte colony stimulating factor (G-CSF) mobilized cluster of
      differentiation (CD) 133(+) cells when combined with percutaneous transluminal angioplasty
      (PTA) in treatment of below the knee (BTK) peripheral arterial disease (PAD) in diabetic
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CD133+ cell, a bone marrow derived subpopulation of adult hematopoietic progenitor cells,
      confers high proliferative, vasculogenic and regenerative capacity in vitro and in vivo.
      thereby suggesting that CD133+ cells may induce vasculogenesis, improve limb perfusion,
      prevent tissue loss and restore ambulatory function in patients with critical limb ischemia.
      Although several small, randomized trials have been conducted so far demonstrating safety of
      autologous cells of bone marrow origin for the treatment, the reported benefits were found to
      be variable. A meta-analysis of autologous bone marrow derived cell therapy for critical limb
      ischemia trials suggested that application of autologous stem cell transplantation in curing
      limb ischemic patients does not have obviously effectiveness in the improvement of ankle
      brachial pressure (ABI) of the limb ischemic patients. But it can dramatically reduce the
      rate of amputation.

      Therefore, in the present study, the investigators aim to evaluate the therapeutic potential
      and safety of transarterial infusion of g-csf-mobilized CD 133(+) cells when combined with
      PTA in treatment of below the knee PAD in diabetic patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Restenosis rate</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of &gt; 50% of restenosis in the treated vessel after 12 months as assessed by digital substraction angiography (DSA) (Efficacy endpoints).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak systolic velocity ratio</measure>
    <time_frame>12 months</time_frame>
    <description>Peak systolic velocity ratio ≥ 2.4 by Doppler's ultrasonography for patients who did not undergo angiography after 12 months (Efficacy endpoints).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe adverse effects (SAEs)</measure>
    <time_frame>12 months</time_frame>
    <description>Number of SAEs per subject across actual treatment cohorts (Safety Endpoint).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ABI value</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Improvement in ABI value by ≥ 0.1 after the procedure and lack of deterioration &gt; 0.15 in relation to the maximal value recorded before the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford classification</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>improvement in Rutherford scale of at least one category after the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcutaneous oxygen pressures (TcPO2)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>.Changes in TcPO2 was assessed at each follow up interval and compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation-free survival (AFS)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Time to below the knee amputation of the ipsilateral leg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rest pain</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Rest pain was measured using Wong-Baker FACES pain rating scale at baseline and each follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six Minute Walk test</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Walking distance, time to onset of leg cramping/pain were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ulcer healing rate</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Ulcer status was assessed at each follow up interval and compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">345</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>G-CSF + CD133(+) cells + PTA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular injection of G-CSF along with transarterial infusion of CD133 (+) cells combined with percutaneous transluminal angioplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTA + G-CSF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous transluminal angioplasty along with intramuscular injection of G-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Only PTA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Only Percutaneous transluminal angioplasty along with placebo infusion of sodium chloride injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>G-CSF + CD133(+) cells</intervention_name>
    <description>Patients in the G-CSF + CD133(+) cells + PTA group, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize CD 133 cells from bone marrow to peripheral blood. After 72-120 hrs, 100 ml suspension of peripheral arterial blood were collected and send to Good Products Manufacturing (GPM) certified laboratory (Shanghai Chen Chuan Biological Material Co. Ltd.) within 24 hrs of obtaining sample to isolate CD 133(+) endothelial progenitor cells (EPC) using magnetic cell separator. Subjects in this group, after vascular PTA treatment, received transarterial infusion of 50 ml suspension of isolated autologous CD 133(+) cells over 30 min via catheter opened into popliteal artery. The infusion of CD 133 cells was repeated after 24 hours.</description>
    <arm_group_label>G-CSF + CD133(+) cells + PTA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>Subjects in this group, after vascular PTA treatment, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize EPCs from bone marrow to peripheral blood. But the C133 (+) cells were not isolated from the peripheral blood to infuse transarterially as in G-CSF + CD133(+) + PTA.</description>
    <arm_group_label>PTA + G-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>percutaneous transluminal angioplasty (PTA)</intervention_name>
    <description>Subjects in this group only underwent below the knee percutaneous transluminal angioplasty .</description>
    <arm_group_label>G-CSF + CD133(+) cells + PTA</arm_group_label>
    <arm_group_label>PTA + G-CSF</arm_group_label>
    <arm_group_label>Only PTA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo infusion</intervention_name>
    <description>Neither G-CSF was injected nor CD133(+) cells. Instead, subjects received placebo infusion (50 ml of 0.9% sodium chloride injection ) over 30 min.</description>
    <arm_group_label>Only PTA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age range: 18-75 years , Gender: Both

          2. Patients with below the knee limb ischemia with diabetes.

          3. Rutherford class 2-6.

          4. Target lesions with a diameter reduction of at least 50% and have an occlusion of
             longer than 4 cm on angiography.

          5. Have no previous history of any stem cell therapy [infusion of CD133 endothelial
             progenitor cell (EPC)].

        Written informed consent signed by the patients or representatives. -

        Exclusion Criteria:

          1. Previous bypass surgery or stent placement at the ipsilateral lower limb

          2. History of intolerance to antiplatelet therapy, heparin, or contrast media.

          3. Presence of any of the following conditions:

               1. severe liver disease (such as ascites, esophageal varices, liver
                  transplantation);

               2. hemodynamic instability;

               3. Severely impaired renal function (serum creatinine level &gt; 2.5 mg/dL).

               4. Receiving immunosuppressive therapy;

               5. History of decompensated heart failure (New York Heart Association class III or
                  IV and level) or myocardial infarction, or heart bypass surgery;

               6. Bleeding diathesis;

               7. Active systemic bacterial infection;

               8. Acute thrombophlebitis or deep vein thrombosis of the target limb; 4) Pregnant or
                  lactating women, or women of child bearing age unable or unwilling to use
                  effective contraception during the study period; 5) Expected survival time of
                  less than 24 months -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mao Q Li, Ph.D</last_name>
    <phone>02166313506</phone>
    <email>cjr.limaoquan@vip.163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Tenth People's Hospital, Tong ji University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mao Q Li, Ph.D</last_name>
      <phone>02166313506</phone>
      <email>cjr.limaoquan@vip.163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ma N, Ladilov Y, Moebius JM, Ong L, Piechaczek C, Dávid A, Kaminski A, Choi YH, Li W, Egger D, Stamm C, Steinhoff G. Intramyocardial delivery of human CD133+ cells in a SCID mouse cryoinjury model: Bone marrow vs. cord blood-derived cells. Cardiovasc Res. 2006 Jul 1;71(1):158-69. Epub 2006 Apr 3.</citation>
    <PMID>16730684</PMID>
  </reference>
  <reference>
    <citation>Gehling UM, Ergün S, Schumacher U, Wagener C, Pantel K, Otte M, Schuch G, Schafhausen P, Mende T, Kilic N, Kluge K, Schäfer B, Hossfeld DK, Fiedler W. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood. 2000 May 15;95(10):3106-12.</citation>
    <PMID>10807776</PMID>
  </reference>
  <reference>
    <citation>Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood. 2000 Feb 1;95(3):952-8.</citation>
    <PMID>10648408</PMID>
  </reference>
  <reference>
    <citation>Friedrich EB, Walenta K, Scharlau J, Nickenig G, Werner N. CD34-/CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res. 2006 Feb 17;98(3):e20-5. Epub 2006 Jan 26.</citation>
    <PMID>16439688</PMID>
  </reference>
  <reference>
    <citation>Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T; Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002 Aug 10;360(9331):427-35.</citation>
    <PMID>12241713</PMID>
  </reference>
  <reference>
    <citation>Esato K, Hamano K, Li TS, Furutani A, Seyama A, Takenaka H, Zempo N. Neovascularization induced by autologous bone marrow cell implantation in peripheral arterial disease. Cell Transplant. 2002;11(8):747-52.</citation>
    <PMID>12588106</PMID>
  </reference>
  <reference>
    <citation>Fadini GP, Avogaro A. Autologous transplantation of granulocyte colony-stimulating factor- mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care. 2006 Feb;29(2):478-9; author reply 479-80.</citation>
    <PMID>16482702</PMID>
  </reference>
  <reference>
    <citation>Miyamoto K, Nishigami K, Nagaya N, Akutsu K, Chiku M, Kamei M, Soma T, Miyata S, Higashi M, Tanaka R, Nakatani T, Nonogi H, Takeshita S. Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans. Circulation. 2006 Dec 12;114(24):2679-84. Epub 2006 Dec 4.</citation>
    <PMID>17145986</PMID>
  </reference>
  <reference>
    <citation>Kawamoto A, Katayama M, Handa N, Kinoshita M, Takano H, Horii M, Sadamoto K, Yokoyama A, Yamanaka T, Onodera R, Kuroda A, Baba R, Kaneko Y, Tsukie T, Kurimoto Y, Okada Y, Kihara Y, Morioka S, Fukushima M, Asahara T. Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial. Stem Cells. 2009 Nov;27(11):2857-64. doi: 10.1002/stem.207.</citation>
    <PMID>19711453</PMID>
  </reference>
  <reference>
    <citation>Lu D, Chen B, Liang Z, Deng W, Jiang Y, Li S, Xu J, Wu Q, Zhang Z, Xie B, Chen S. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract. 2011 Apr;92(1):26-36. doi: 10.1016/j.diabres.2010.12.010. Epub 2011 Jan 8.</citation>
    <PMID>21216483</PMID>
  </reference>
  <reference>
    <citation>Losordo DW, Kibbe MR, Mendelsohn F, Marston W, Driver VR, Sharafuddin M, Teodorescu V, Wiechmann BN, Thompson C, Kraiss L, Carman T, Dohad S, Huang P, Junge CE, Story K, Weistroffer T, Thorne TM, Millay M, Runyon JP, Schainfeld R; Autologous CD34+ Cell Therapy for Critical Limb Ischemia Investigators. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circ Cardiovasc Interv. 2012 Dec;5(6):821-30. doi: 10.1161/CIRCINTERVENTIONS.112.968321. Epub 2012 Nov 27.</citation>
    <PMID>23192920</PMID>
  </reference>
  <reference>
    <citation>Sun X, Ying J, Wang Y, Li W, Wu Y, Yao B, Liu Y, Gao H, Zhang X. Meta-analysis on autologous stem cell transplantation in the treatment of limb ischemic. Int J Clin Exp Med. 2015 Jun 15;8(6):8740-8. eCollection 2015.</citation>
    <PMID>26309525</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2016</study_first_submitted>
  <study_first_submitted_qc>September 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2016</study_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 10th People's Hospital</investigator_affiliation>
    <investigator_full_name>Maoquan Li</investigator_full_name>
    <investigator_title>Prof. Dr. Li</investigator_title>
  </responsible_party>
  <keyword>Endothelial progenitor cell</keyword>
  <keyword>Percutaneous transluminal angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

